Plus Therapeutics Stock Filter Stocks by Fundamentals
| PSTV Stock | USD 1.28 0.05 4.07% |
Plus Therapeutics fundamentals help investors to digest information that contributes to Plus Therapeutics' financial success or failures. It also enables traders to predict the movement of Plus Stock. The fundamental analysis module provides a way to measure Plus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Plus Therapeutics stock.
Plus | Shares Owned by Institutions |
Plus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Plus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Plus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Plus Therapeutics' value.| Shares | Citadel Advisors Llc | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Aigh Capital Management, Llc | 2024-09-30 | 560.9 K | Geode Capital Management, Llc | 2024-09-30 | 54.3 K | Vanguard Group Inc | 2024-09-30 | 32.5 K | Blackrock Inc | 2024-06-30 | 7 K | Tower Research Capital Llc | 2024-06-30 | 4.2 K | Ubs Group Ag | 2024-06-30 | 3.2 K | Advisor Group Holdings, Inc. | 2024-06-30 | 133 | Jpmorgan Chase & Co | 2024-06-30 | 100.0 | Bank Of America Corp | 2024-06-30 | 47.0 |
Plus Fundamentals
| Return On Equity | -5.22 | ||||
| Return On Asset | -0.69 | ||||
| Profit Margin | (2.40) % | ||||
| Operating Margin | (2.89) % | ||||
| Current Valuation | 5.86 M | ||||
| Shares Outstanding | 5.9 M | ||||
| Shares Owned By Insiders | 2.34 % | ||||
| Shares Owned By Institutions | 11.30 % | ||||
| Number Of Shares Shorted | 52.34 K | ||||
| Price To Book | 3.76 X | ||||
| Price To Sales | 1.32 X | ||||
| Revenue | 4.91 M | ||||
| Gross Profit | (9.47 M) | ||||
| EBITDA | (12.69 M) | ||||
| Net Income | (13.32 M) | ||||
| Cash And Equivalents | 20.27 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 4.18 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 2.81 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (12.85 M) | ||||
| Short Ratio | 0.98 X | ||||
| Earnings Per Share | (2.37) X | ||||
| Target Price | 16.0 | ||||
| Number Of Employees | 20 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 7.25 M | ||||
| Total Asset | 11.39 M | ||||
| Retained Earnings | (480.5 M) | ||||
| Working Capital | (893 K) | ||||
| Net Asset | 11.39 M |
About Plus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Plus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Plus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Plus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.